Premature atrial contraction

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

Retrieved on: 
Thursday, August 25, 2022

The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.

Key Points: 
  • The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.
  • Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus and a limited number of patients infected with influenza B virus.
  • RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
  • Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.

Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System

Retrieved on: 
Monday, January 10, 2022

The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved in Japan in 2017 for patients who only require single-chamber pacing.

Key Points: 
  • The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved in Japan in 2017 for patients who only require single-chamber pacing.
  • "The first Micra system transformed the concept of pacemakers by eliminating surgical pockets and leads, and Micra AV promises to deliver the benefits of leadless pacing to a larger number of patients because ventricular pacing can be performed synchronously with the atrium."
  • Identical in size and shape to the original Micra TPS, Micra AV has several additional algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block.
  • The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile

Retrieved on: 
Wednesday, September 1, 2021

We are pleased to provide additional doses of RAPIVAB to the SNS as we enter another influenza season of unpredictable severity, said Dr. William Sheridan, chief medical officer of BioCryst.

Key Points: 
  • We are pleased to provide additional doses of RAPIVAB to the SNS as we enter another influenza season of unpredictable severity, said Dr. William Sheridan, chief medical officer of BioCryst.
  • With the fulfillment of this new order, BioCryst will have delivered 40,000 doses under the contract.
  • Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.
  • Cases of anaphylaxis and serious skin/hypersensitivity reactions such as Stevens-Johnson syndrome and erythema multiforme have occurred with RAPIVAB.

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

Retrieved on: 
Thursday, June 3, 2021

Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.

Key Points: 
  • Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.
  • The new patent will expand the use of ANAVEX2-73 (blarcamesine) from neurodegenerative and neurodevelopmental disorders to a range of cardiac dysfunctions.
  • It includes cardiac arrhythmia, premature ventricular contraction (PVC), ventricular dysfunction, ventricular arrhythmia, atrial fibrillation, and atrial flutter, among others.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Coala first smartphone ECG to detect 9 different arrhythmias during COVID-19

Retrieved on: 
Tuesday, April 28, 2020

The expansion makes the Coala Heart Monitor the only smartphone-powered ECG solution in the world that automatically detects nine of the most common heart arrhythmias as well as normal sinus rhythm.

Key Points: 
  • The expansion makes the Coala Heart Monitor the only smartphone-powered ECG solution in the world that automatically detects nine of the most common heart arrhythmias as well as normal sinus rhythm.
  • "The ability with Coala to monitor patients remotely and obtain real-time ECG analysis of these most common arrhythmias offers progress in the care of patients who are at increased risk of various arrhythmias, some of which are life-threatening.
  • The Coala Heart Monitor is an FDA-cleared and CE Class IIa medical device system intended for remote cardiac monitoring using advanced algorithms to detect arrythmias as Atrial Fibrillation (AF).
  • Effective immediately, the Coala Heart Monitor will also be able to detect and show ECG results for common arrhythmias such as AV Block II, tachycardia, multiple Premature Atrial Contractions (PAC's) and multiple Premature Ventricular Contractions (PVC's).